Manufacturers Life Insurance Company, The Macrogenics Inc Transaction History

Manufacturers Life Insurance Company, The

  • $109 Billion
  • Q4 2024

A detailed history of Manufacturers Life Insurance Company, The transactions in Macrogenics Inc stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 121,026 shares of MGNX stock, worth $290,462. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,026
Previous 121,278 0.21%
Holding current value
$290,462
Previous $399,000 1.5%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$3.18 - $4.46 $801 - $1,123
-252 Reduced 0.21%
121,026 $393,000
Q3 2024

Nov 13, 2024
SELL
$3.0 - $5.55 $2,262 - $4,184
-754 Reduced 0.62%
121,278 $399,000
Q2 2024

Aug 14, 2024
BUY
$3.31 - $18.51 $8,218 - $45,960
2,483 Added 2.08%
122,032 $518,000
Q1 2024

May 14, 2024
BUY
$9.77 - $21.47 $948,520 - $2.08 Million
97,085 Added 432.18%
119,549 $1.76 Million
Q4 2023

Feb 13, 2024
SELL
$4.48 - $10.11 $14,712 - $33,201
-3,284 Reduced 12.75%
22,464 $216,000
Q3 2023

Nov 15, 2023
SELL
$4.48 - $6.19 $241 - $334
-54 Reduced 0.21%
25,748 $119,000
Q2 2023

Aug 11, 2023
BUY
$4.62 - $7.54 $7,359 - $12,011
1,593 Added 6.58%
25,802 $138,000
Q4 2022

Aug 11, 2023
SELL
$3.34 - $6.98 $8,613 - $18,001
-2,579 Reduced 9.63%
24,209 $162,000
Q4 2022

Feb 13, 2023
SELL
$3.34 - $6.98 $8,613 - $18,001
-2,579 Reduced 9.63%
24,209 $162,000
Q3 2022

Aug 11, 2023
SELL
$3.01 - $5.22 $3,085 - $5,350
-1,025 Reduced 3.69%
26,788 $81,000
Q3 2022

Nov 03, 2022
SELL
$3.01 - $5.22 $3,085 - $5,350
-1,025 Reduced 3.69%
26,788 $93,000
Q2 2022

Aug 11, 2023
BUY
$2.25 - $9.99 $5,796 - $25,734
2,576 Added 10.21%
27,813 $82,000
Q2 2022

Aug 15, 2022
BUY
$2.25 - $9.99 $5,796 - $25,734
2,576 Added 10.21%
27,813 $82,000
Q1 2022

Aug 11, 2023
BUY
$8.12 - $16.9 $8,347 - $17,373
1,028 Added 4.25%
25,237 $222,000
Q1 2022

May 20, 2022
SELL
$8.12 - $16.9 $50,027 - $104,120
-6,161 Reduced 19.62%
25,237 $222,000
Q4 2021

Feb 16, 2022
BUY
$15.91 - $21.88 $4,295 - $5,907
270 Added 0.87%
31,398 $504,000
Q3 2021

Nov 12, 2021
SELL
$19.74 - $28.7 $39,795 - $57,859
-2,016 Reduced 6.08%
31,128 $652,000
Q2 2021

Aug 12, 2021
BUY
$20.49 - $35.63 $47,844 - $83,196
2,335 Added 7.58%
33,144 $890,000
Q1 2021

May 03, 2021
SELL
$18.99 - $33.2 $35,853 - $62,681
-1,888 Reduced 5.77%
30,809 $981,000
Q4 2020

Feb 12, 2021
BUY
$19.41 - $26.0 $51,222 - $68,614
2,639 Added 8.78%
32,697 $747,000
Q3 2020

Nov 09, 2020
BUY
$24.69 - $31.6 $35,899 - $45,946
1,454 Added 5.08%
30,058 $757,000
Q2 2020

Aug 10, 2020
SELL
$5.2 - $29.12 $13,442 - $75,275
-2,585 Reduced 8.29%
28,604 $809,000
Q1 2020

May 15, 2020
BUY
$4.28 - $12.11 $8,333 - $23,578
1,947 Added 6.66%
31,189 $182,000
Q4 2019

Feb 14, 2020
SELL
$7.95 - $12.27 $5,493 - $8,478
-691 Reduced 2.31%
29,242 $318,000
Q2 2019

Aug 14, 2019
BUY
$14.51 - $19.71 $57,488 - $78,091
3,962 Added 15.26%
29,933 $508,000
Q1 2019

May 13, 2019
BUY
$11.11 - $25.6 $10,321 - $23,782
929 Added 3.71%
25,971 $467,000
Q4 2018

Feb 14, 2019
SELL
$11.75 - $21.42 $18,612 - $33,929
-1,584 Reduced 5.95%
25,042 $318,000
Q3 2018

Nov 14, 2018
SELL
$19.26 - $23.46 $62,960 - $76,690
-3,269 Reduced 10.93%
26,626 $571,000
Q2 2018

Aug 14, 2018
BUY
$19.78 - $24.67 $81,612 - $101,788
4,126 Added 16.01%
29,895 $617,000
Q1 2018

May 15, 2018
SELL
$18.89 - $32.46 $16,604 - $28,532
-879 Reduced 3.3%
25,769 $648,000
Q4 2017

Feb 08, 2018
BUY
$16.19 - $20.3 $2,477 - $3,105
153 Added 0.58%
26,648 $506,000
Q3 2017

Nov 14, 2017
BUY
$15.52 - $18.94 $411,202 - $501,815
26,495
26,495 $489,000

Others Institutions Holding MGNX

# of Institutions
131
Shares Held
56M
Call Options Held
28.3K
Put Options Held
197K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $148M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email